The global cancer therapeutics market was valued at USD 212.58 billion in 2025 and is projected to reach approximately USD 469.38 billion by 2034, growing at a CAGR of 9.20% during the forecast period. This growth is driven by the increasing prevalence of cancer, advancements in therapeutic technologies, and expanding access to oncology care worldwide.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Therapeutics Market, by Top Selling Drugs Type
8.1.1. Revlimid
8.1.1.1. Market Revenue and Forecast
8.1.2. Avastin
8.1.2.1. Market Revenue and Forecast
8.1.3. Herceptin
8.1.3.1. Market Revenue and Forecast
8.1.4. Rituxan
8.1.4.1. Market Revenue and Forecast
8.1.5. Opdivo
8.1.5.1. Market Revenue and Forecast
8.1.6. Gleevec
8.1.6.1. Market Revenue and Forecast
8.1.7. Velcade
8.1.7.1. Market Revenue and Forecast
8.1.8. Imbruvica
8.1.8.1. Market Revenue and Forecast
8.1.9. Ibrance
8.1.9.1. Market Revenue and Forecast
8.1.10. Zytiga
8.1.10.1. Market Revenue and Forecast
8.1.11. Alimta
8.1.11.1. Market Revenue and Forecast
8.1.12. Xtandi
8.1.12.1. Market Revenue and Forecast
8.1.13. Tarceva
8.1.13.1. Market Revenue and Forecast
8.1.14. Perjeta
8.1.14.1. Market Revenue and Forecast
8.1.15. Temodar
8.1.15.1. Market Revenue and Forecast
8.1.16. Others
8.1.16.1. Market Revenue and Forecast
9.1. Cancer Therapeutics Market, by Application
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast
9.1.3. Colorectal Cancer
9.1.3.1. Market Revenue and Forecast
9.1.4. Prostate Cancer
9.1.4.1. Market Revenue and Forecast
9.1.5. Breast Cancer
9.1.5.1. Market Revenue and Forecast
9.1.6. Cervical Cancer
9.1.6.1. Market Revenue and Forecast
9.1.7. Head and Neck Cancer
9.1.7.1. Market Revenue and Forecast
9.1.8. Glioblastoma
9.1.8.1. Market Revenue and Forecast
9.1.9. Malignant Meningioma
9.1.9.1. Market Revenue and Forecast
9.1.10. Mesothelioma
9.1.10.1. Market Revenue and Forecast
9.1.11. Melanoma
9.1.11.1. Market Revenue and Forecast
9.1.12. Others
9.1.12.1. Market Revenue and Forecast
10.1. Cancer Therapeutics Market, by End User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Cancer and Radiation Therapy Centers
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Top Selling Drugs
11.1.2. Market Revenue and Forecast, by Application
11.1.3. Market Revenue and Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Top Selling Drugs
11.1.4.2. Market Revenue and Forecast, by Application
11.1.4.3. Market Revenue and Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Top Selling Drugs
11.1.5.2. Market Revenue and Forecast, by Application
11.1.5.3. Market Revenue and Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Top Selling Drugs
11.2.2. Market Revenue and Forecast, by Application
11.2.3. Market Revenue and Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Top Selling Drugs
11.2.4.2. Market Revenue and Forecast, by Application
11.2.4.3. Market Revenue and Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Top Selling Drugs
11.2.5.2. Market Revenue and Forecast, by Application
11.2.5.3. Market Revenue and Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Top Selling Drugs
11.2.6.2. Market Revenue and Forecast, by Application
11.2.6.3. Market Revenue and Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Top Selling Drugs
11.2.7.2. Market Revenue and Forecast, by Application
11.2.7.3. Market Revenue and Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Top Selling Drugs
11.3.2. Market Revenue and Forecast, by Application
11.3.3. Market Revenue and Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Top Selling Drugs
11.3.4.2. Market Revenue and Forecast, by Application
11.3.4.3. Market Revenue and Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Top Selling Drugs
11.3.5.2. Market Revenue and Forecast, by Application
11.3.5.3. Market Revenue and Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Top Selling Drugs
11.3.6.2. Market Revenue and Forecast, by Application
11.3.6.3. Market Revenue and Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Top Selling Drugs
11.3.7.2. Market Revenue and Forecast, by Application
11.3.7.3. Market Revenue and Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Top Selling Drugs
11.4.2. Market Revenue and Forecast, by Application
11.4.3. Market Revenue and Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Top Selling Drugs
11.4.4.2. Market Revenue and Forecast, by Application
11.4.4.3. Market Revenue and Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Top Selling Drugs
11.4.5.2. Market Revenue and Forecast, by Application
11.4.5.3. Market Revenue and Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Top Selling Drugs
11.4.6.2. Market Revenue and Forecast, by Application
11.4.6.3. Market Revenue and Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Top Selling Drugs
11.4.7.2. Market Revenue and Forecast, by Application
11.4.7.3. Market Revenue and Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Top Selling Drugs
11.5.2. Market Revenue and Forecast, by Application
11.5.3. Market Revenue and Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Top Selling Drugs
11.5.4.2. Market Revenue and Forecast, by Application
11.5.4.3. Market Revenue and Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Top Selling Drugs
11.5.5.2. Market Revenue and Forecast, by Application
11.5.5.3. Market Revenue and Forecast, by End User
12.1. F. Hoffmann-La Roche AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AbbVie, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Johnson & Johnson
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Celgene Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AstellasPharma, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck KGaA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eli Lilly and Company
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description